Historique
Article de Périodique
A randomized trial of e-cigarettes versus nicotine-replacement therapy (2019)
Auteur(s) :
HAJEK, P. ;
PHILLIPS-WALLER, A. ;
PRZULJ, D. ;
PESOLA, F. ;
MYERS SMITH, K. ;
BISAL, N. ;
LI, J. ;
PARROTT, S. ;
SASIENI, P. ;
DAWKINS, L. ;
ROSS, L. ;
GONIEWICZ, M. ;
WU, Q. ;
MCROBBIE, H. J.
Année :
2019
Page(s) :
9 p., doi: 10.1056/NEJMoa1808779
Langue(s) :
Anglais
Refs biblio. :
26
Domaine :
Tabac / Tobacco / e-cigarette
Thésaurus géographique
ROYAUME-UNI
Thésaurus mots-clés
E-CIGARETTE
;
SUBSTITUTS NICOTINIQUES
;
ETUDE RANDOMISEE
;
COMPARAISON
;
SEVRAGE
;
EFFICACITE
;
ABSTINENCE
Note générale :
Editorial: E-cigarettes to assist with smoking cessation. Borrelli B., O'Connor G.T., p. 678-679.
Résumé :
Background: E-cigarettes are commonly used in attempts to stop smoking, but evidence is limited regarding their effectiveness as compared with that of nicotine products approved as smoking-cessation treatments.
Methods: We randomly assigned adults attending U.K. National Health Service stop-smoking services to either nicotine-replacement products of their choice, including product combinations, provided for up to 3 months, or an e-cigarette starter pack (a second-generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg per milliliter]), with a recommendation to purchase further e-liquids of the flavor and strength of their choice. Treatment included weekly behavioral support for at least 4 weeks. The primary outcome was sustained abstinence for 1 year, which was validated biochemically at the final visit. Participants who were lost to follow-up or did not provide biochemical validation were considered to not be abstinent. Secondary outcomes included participant-reported treatment usage and respiratory symptoms.
Results: A total of 886 participants underwent randomization. The 1-year abstinence rate was 18.0% in the e-cigarette group, as compared with 9.9% in the nicotine-replacement group (relative risk, 1.83; 95% confidence interval [CI], 1.30 to 2.58; P Conclusions: E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy, when both products were accompanied by behavioral support. (Funded by the National Institute for Health Research and Cancer Research UK; Current Controlled Trials number, ISRCTN60477608.)
Methods: We randomly assigned adults attending U.K. National Health Service stop-smoking services to either nicotine-replacement products of their choice, including product combinations, provided for up to 3 months, or an e-cigarette starter pack (a second-generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg per milliliter]), with a recommendation to purchase further e-liquids of the flavor and strength of their choice. Treatment included weekly behavioral support for at least 4 weeks. The primary outcome was sustained abstinence for 1 year, which was validated biochemically at the final visit. Participants who were lost to follow-up or did not provide biochemical validation were considered to not be abstinent. Secondary outcomes included participant-reported treatment usage and respiratory symptoms.
Results: A total of 886 participants underwent randomization. The 1-year abstinence rate was 18.0% in the e-cigarette group, as compared with 9.9% in the nicotine-replacement group (relative risk, 1.83; 95% confidence interval [CI], 1.30 to 2.58; P Conclusions: E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy, when both products were accompanied by behavioral support. (Funded by the National Institute for Health Research and Cancer Research UK; Current Controlled Trials number, ISRCTN60477608.)
Affiliation :
Queen Mary University of London; King's College London; London South Bank University, London; University of York, York; Leicester City Council, Leicester, UK